Click for best price
Postpemic Era NextGeneration Breast Cancer Diagnostic Screening Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Next-Generation Breast Cancer Diagnostic and Screening industry at home and abroad, estimate the overall market scale of the Next-Generation Breast Cancer Diagnostic and Screening industry and the market share of major countries, Next-Generation Breast Cancer Diagnostic and Screening industry, and study and judge the downstream market demand of Next-Generation Breast Cancer Diagnostic and Screening through systematic research, Analyze the competition pattern of Next-Generation Breast Cancer Diagnostic and Screening, so as to help solve the pain points of various stakeholders in Next-Generation Breast Cancer Diagnostic and Screening industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Next-Generation Breast Cancer Diagnostic and Screening Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Next-Generation Breast Cancer Diagnostic and Screening Market?
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
Major Type of Next-Generation Breast Cancer Diagnostic and Screening Covered in XYZResearch report:
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)
Application Segments Covered in XYZResearch Market
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
98 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Value
2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type
2.2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Value
2.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Sales
2.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Sales by Type
2.3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Sales
3. The Major Driver of Next-Generation Breast Cancer Diagnostic and Screening Industry
3.1 Historical & Forecast Global Next-Generation Breast Cancer Diagnostic and Screening Sales and Revenue (2018-2028)
3.2 Largest Application for Next-Generation Breast Cancer Diagnostic and Screening (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Next-Generation Breast Cancer Diagnostic and Screening Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Next-Generation Breast Cancer Diagnostic and Screening Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Next-Generation Breast Cancer Diagnostic and Screening Average Price Trend
13.1 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in US (2018-2022)
13.2 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Europe (2018-2022)
13.3 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in China (2018-2022)
13.4 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Japan (2018-2022)
13.5 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in India (2018-2022)
13.6 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Korea (2018-2022)
13.7 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Next-Generation Breast Cancer Diagnostic and Screening Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Next-Generation Breast Cancer Diagnostic and Screening
15. Next-Generation Breast Cancer Diagnostic and Screening Competitive Landscape
15.1 Abbott Laboratories
15.1.1 Abbott Laboratories Company Profiles
15.1.2 Abbott Laboratories Product Introduction
15.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Agendia
15.2.1 Agendia Company Profiles
15.2.2 Agendia Product Introduction
15.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Agilent Technologies
15.3.1 Agilent Technologies Company Profiles
15.3.2 Agilent Technologies Product Introduction
15.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Ambry Genetics
15.4.1 Ambry Genetics Company Profiles
15.4.2 Ambry Genetics Product Introduction
15.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Biocept
15.5.1 Biocept Company Profiles
15.5.2 Biocept Product Introduction
15.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Biotheranostics
15.6.1 Biotheranostics Company Profiles
15.6.2 Biotheranostics Product Introduction
15.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Centogene
15.7.1 Centogene Company Profiles
15.7.2 Centogene Product Introduction
15.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Danaher Corporation
15.8.1 Danaher Corporation Company Profiles
15.8.2 Danaher Corporation Product Introduction
15.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 EXACT Sciences Corporation
15.9.1 EXACT Sciences Corporation Company Profiles
15.9.2 EXACT Sciences Corporation Product Introduction
15.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Roche Holding AG
15.10.1 Roche Holding AG Company Profiles
15.10.2 Roche Holding AG Product Introduction
15.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Fulgent Genetics
15.12 Illumina
15.13 Invitae
15.14 Lucence Diagnostics Pte Ltd
15.15 Myriad Genetics
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Next-Generation Breast Cancer Diagnostic and Screening Industry (Volume)
Figure 2. Next-Generation Breast Cancer Diagnostic and Screening Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022
Figure 5. US Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Next-Generation Breast Cancer Diagnostic and Screening Revenue, by Type (Million USD) (2018-2028)
Table 4. Next-Generation Breast Cancer Diagnostic and Screening Sales, by Type (K Unit) (2018-2028)
Table 5. Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit) by Application (2018-2028)
Table 6. Next-Generation Breast Cancer Diagnostic and Screening Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Abbott Laboratories Profiles
Table 61. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 62. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Abbott Laboratories Strategic initiatives
Table 64. Agendia Profiles
Table 65. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 66. Agendia Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Agendia Strategic initiatives
Table 68. Agilent Technologies Profiles
Table 69. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 70. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Agilent Technologies Strategic initiatives
Table 72. Ambry Genetics Profiles
Table 73. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 74. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Ambry Genetics Strategic initiatives
Table 76. Biocept Profiles
Table 77. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 78. Biocept Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Biocept Strategic initiatives
Table 80. Biotheranostics Profiles
Table 81. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 82. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Biotheranostics Strategic initiatives
Table 84. Centogene Profiles
Table 85. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 86. Centogene Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Centogene Strategic initiatives
Table 88. Danaher Corporation Profiles
Table 89. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 90. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Danaher Corporation Strategic initiatives
Table 92. EXACT Sciences Corporation Profiles
Table 93. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 94. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. EXACT Sciences Corporation Strategic initiatives
Table 97. Roche Holding AG Profiles
Table 98. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 99. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Roche Holding AG Strategic initiatives
Table 101. Fulgent Genetics Profiles
Table 102. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 103. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Fulgent Genetics Strategic initiatives
Table 105. Illumina Profiles
Table 106. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 107. Illumina Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Illumina Strategic initiatives
Table 109. Invitae Profiles
Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 111. Invitae Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Invitae Strategic initiatives
Table 113. Lucence Diagnostics Pte Ltd Profiles
Table 114. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Lucence Diagnostics Pte Ltd Strategic initiatives
Table 117. Myriad Genetics Profiles
Table 118. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Introduction
Table 119. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. Myriad Genetics Strategic initiatives
